Last updated: July 20, 2026
BioCryst Pharmaceuticals, Inc. v. Annora Pharma Private Limited (1:25-cv-00281): Litigation Summary, Claims at Issue, and What It Means for Generic Entry
BioCryst Pharmaceuticals, Inc. v. Annora Pharma Private Limited is docketed as 1:25-cv-00281 (filed in 2025). The matter’s public record is not provided here with enough detail to identify the asserted patents, causes of action, claim construction posture, any Paragraph IV certifications, or the specific FDA product(s) implicated. Without those case-specific elements, a complete and accurate litigation summary and analysis cannot be produced.
What patents are asserted in BioCryst v. Annora Pharma (1:25-cv-00281)?
A litigation summary requires, at minimum, the patent numbers listed in the complaint, whether the suit is a Hatch-Waxman (35 U.S.C. § 271(e)(2)) action linked to an ANDA, or a non-Hatch-Waxman IP dispute. Those identifiers are not included in the information provided.
Which parties are the patent holders and defendants?
A proper case analysis distinguishes between:
- BioCryst entities and any affiliate assignees
- Annora Pharma’s role (ANDA filer vs. contract manufacturer vs. distributor)
- Any additional named entities
No party-level detail is available here.
Are method-of-use or formulation patents part of the asserted estate?
A business-relevant analysis depends on whether asserted claims target:
- active ingredient composition
- salt/polymorph/crystal form
- formulation (oral solid, capsule, tablet, excipient systems)
- method-of-treatment / dosing regimens
The asserted patent categories are not provided.
Is this an ANDA Paragraph IV case or a different IP theory?
Hatch-Waxman patent litigation typically ties to:
- ANDA (ANDA filer identity)
- Orange Book listed patents
- Paragraph IV notice date
- FDA approval status and 180-day exclusivity triggers
None of these case linkage details are available here.
When can generic or biosimilar entry occur if BioCryst wins or loses?
The entry timeline in patent cases depends on:
- whether claims are enjoined
- whether the court grants preliminary relief
- whether the patents are found invalid or not infringed
- any settlement terms affecting launch dates
No injunction posture, scheduling orders, trial dates, or settlement information is available here.
What does the case history say: transfer, consolidation, Markman, or trial setting?
A litigation analysis typically reports:
- complaint filing date and venue
- any motions to dismiss or for summary judgment
- Markman hearing timing
- claim construction rulings
- trial date and dispositive motion deadlines
Those procedural dates are not included.
How strong is BioCryst’s patent case in this dispute?
Patent-strength analysis depends on:
- claim scope in the asserted patents
- prior art landscape and enablement history
- prosecution history relevant to interpretation
- prior litigations or PTAB outcomes on the same patents
None of that information is available here.
Which Orange Book patents are implicated by the BioCryst vs. Annora dispute?
For Hatch-Waxman cases, the Orange Book mapping is essential:
- patent list (drug product, strength, dosage form)
- “active” Orange Book status
- regulatory exclusivity expirations
- whether patents are “listed for the drug” at issue
No Orange Book identifiers are included.
What settlement terms typically appear in BioCryst-type Hatch-Waxman cases?
If the case is Hatch-Waxman and if a settlement occurs, analysts look for:
- stipulated launch dates
- covenant not to sue scope
- dismissal with or without prejudice
- patent carve-outs and design-around provisions
- payments or “non-cash” consideration provisions
No settlement terms are provided here.
What generic entry risks exist for Annora Pharma’s product profile?
Risk assessment requires:
- whether Annora’s product is design-around validated
- whether the product is a controlled release vs immediate release
- whether the asserted composition or method claims cover manufacturing route
- whether bioequivalence strategy triggers different claim exposure
No product or technical details are available here.
How does BioCryst’s broader litigation strategy compare with similar disputes?
A comparative strategy review needs:
- other cases in the same patent family
- recurring defendants
- outcomes (validity, infringement, final judgment)
- time-to-judgment metrics
No related-case list is provided.
Key Takeaways
- A complete litigation summary cannot be produced from the information supplied because the record lacks the case-specific elements required for factual accuracy: asserted patents, asserted claims, FDA/ANDA linkages, procedural posture, and any settlement or injunction details.
FAQs
- What documents define the asserted patent claims in 1:25-cv-00281?
- Does BioCryst’s suit rely on 35 U.S.C. § 271(e)(2) and a Paragraph IV notice?
- Which Orange Book patents correspond to the BioCryst-listed drug product at issue?
- What is the typical outcome range for preliminary injunction motions in Hatch-Waxman cases like this?
- If a settlement occurs, what launch-date constraints are most commonly included?
References (APA)
No sources were provided in the prompt, and no citation-ready case record is included here.
